Eltrombopag For Immune Thrombocytopenic Children in a Single Region.

Child patients of chronic thrombocytopenic purpura with severe and resistant thrombocytopenia were evaluated to observe whether their clinical or laboratory states improve by one of the thrombomimetic therapeutic agent called Eltrombopag as in adults in a single center of different country from previous studies. Nineteen patients with chronic immune thrombocytopenia were treated with Eltrombopag to dose in international guidelines. Approximately half (11/19:58%) of the patients benefitted from the treatment with Eltrombopag either by an increase of platelet levels at safe levels with a decrease in the frequency of bleedings which needed rescue treatment. Thrombomimetic treatment options have strengthened the clinician's hand where the regular treatment options became insufficient.